Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriMix-DC vaccination plus lenalidomide maintenance after first autologous stem cell transplantation in multiple myeloma
2013-000795-15Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Sep 2013
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TriMix-DC and lenalidomide in multiple myeloma (MM), sponsored by UZ Brussel. Started Sep 2013; status: completed.
02
Drugs
TriMix-DClenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-000795-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000795-15.